Surgical Treatment of Canine Glaucoma

Bras, Dineli; Maggio, Federica

doi:10.1016/j.cvsm.2015.06.007

Cited by 28 publications

(35 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on these factors, long‐term success rates for IOP control and preservation of sight vary considerably, but tend to improve with more advanced technologies and modifications of surgical techniques. The most recently published 1‐year success rates of canine glaucoma surgery for both IOP control and sight preservation are ~90% for Ahmed valved drainage implants, 65%‐75% for Baerveldt nonvalved glaucoma drainage device, 41%‐92% for transscleral cyclophotocoagulation (TSCP) alone or in combination with the placement of Ahmed valved drainage implants, and 72%‐74% for endolaser cyclophotocoagulation (ECP) . Even though we have to be careful when comparing human and canine studies because of different study designs, inclusion/exclusion criteria, and specific outcome measures, these canine success rates are comparable to published results in human patients for Ahmed and Baerveldt drainage devices (ClinicalTrials.gov Identifier: NCT00376363) .…”

Section: Novel Surgical Therapies To Control Iopmentioning

confidence: 99%

“…Despite the recent emergence of ECP (see below), diode laser TSCP is still widely used by veterinary ophthalmologists, either as a sole surgical tool or in combination with the placement of a drainage implant . While TSCP is relatively noninvasive and easy to perform, the long‐term success rate tends to be lower (50%‐92% IOP control and 50%‐53% vision at 1‐year post‐TSCP), unless the laser treatment is combined with drainage implants . Vision‐threatening complications associated with conventional TSCP include immediate IOP elevation, corneal ulceration, retinal detachment, hemorrhage, and hypotony with resulting phthisis bulbi.…”

Section: Novel Surgical Therapies To Control Iopmentioning

confidence: 99%

“…Vision‐threatening complications associated with conventional TSCP include immediate IOP elevation, corneal ulceration, retinal detachment, hemorrhage, and hypotony with resulting phthisis bulbi. Most of these adverse effects are due to the nonselective destruction of adjacent tissues because of the high temperatures reached in the target tissue . A novel technique currently being evaluated for TSCP is the use of micropulse laser (Figure ; MicroPulse ® Cyclo G6; Iridex) .…”

Section: Novel Surgical Therapies To Control Iopmentioning

confidence: 99%

“…Diode ECP is an attractive alternative to TSCP in the treatment of canine glaucoma. It is combined with lens removal by phacoemulsification, or it also can be used for prophylactic treatment combined with cataract removal in dogs at increased risk of glaucoma development . The main advantage of ECP over TSCP is that the ciliary processes and the laser treatment effect can be visualized directly through an endoscope, allowing the use of more controlled application of significantly less laser energy (Figure ).…”

Section: Novel Surgical Therapies To Control Iopmentioning

confidence: 99%

“…Currently, the most commonly used surgical techniques for canine glaucoma are placement of drainage implants to shunt aqueous humor to equatorial bleb-promoting reservoirs ( Figure 5), cyclodestructive techniques to reduce aqueous humor production, and combinations of these two methods. 58,59 Even though recently introduced surgical methods appear promising with increased success rates, they are often associated with intensive postoperative care and considerable expense, and a substantial number of affected dogs still go blind. The method of choice is based on clinician preference and cost to owner, and is influenced by factors such as breed, type and stage of glaucoma, and surgeon experience.…”

Section: Therapies To Control Iopmentioning

confidence: 99%

See 4 more Smart Citations

The future of canine glaucoma therapy

Komàromy

Bras²,

Esson

et al. 2019

Veterinary Ophthalmology

Self Cite

View full text Add to dashboard Cite

Canine glaucoma is a group of disorders that are generally associated with increased intraocular pressure (IOP) resulting in a characteristic optic neuropathy. Glaucoma is a leading cause of irreversible vision loss in dogs and may be either primary or secondary. Despite the growing spectrum of medical and surgical therapies, there is no cure, and many affected dogs go blind. Often eyes are enucleated because of painfully high, uncontrollable IOP. While progressive vision loss due to primary glaucoma is considered preventable in some humans, this is mostly not true for dogs. There is an urgent need for more effective, affordable treatment options. Because newly developed glaucoma medications are emerging at a very slow rate and may not be effective in dogs, work toward improving surgical options may be the most rewarding approach in the near term. This Viewpoint Article summarizes the discussions and recommended research strategies of both a Think Tank and a Consortium focused on the development of more effective therapies for canine glaucoma; both were organized and funded by the American College of Veterinary Ophthalmologists Vision for Animals Foundation (ACVO‐VAF). The recommendations consist of (a) better understanding of disease mechanisms, (b) early glaucoma diagnosis and disease staging, (c) optimization of IOP‐lowering medical treatment, (d) new surgical therapies to control IOP, and (e) novel treatment strategies, such as gene and stem cell therapies, neuroprotection, and neuroregeneration. In order to address these needs, increases in research funding specifically focused on canine glaucoma are necessary.

show abstract